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Background: There are an established and growing number of Mendelian genetic causes for chronic kidney
disease (CKD) in adults, though estimates of prevalence have been speculative. The CKD Queensland (CKD.QLD)
registry enables partial clarification of this through the study of adults with CKD receiving nephrology care
throughout Queensland, Australia.
Methods: Data from the first 2,935 patients consented to the CKD.QLD registry across five sites was analysed, with
a comparison between those with and without Genetic Renal Disease (GRD). Prevalence of GRD amongst those
with diagnosed CKD, the general population, and commencing renal replacement therapy (RRT) was calculated
using the CKD.QLD registry, national census data and extracted Australian and New Zealand Dialysis and
Transplantation (ANZDATA) registry report data respectively.
Results: Patients with GRD constituted 9.8% of this Australian adult CKD cohort (287/2935). This was lower than in
local incident RRT cohorts (2006–2011: 9.8% vs 11.3%, x2 = 0.014). Cases of adult CKD GRD were more likely to be
female (54.0% vs 45.6%; x2 = 0.007), younger (mean 52.6 yrs vs 69.3 yrs, p < 0.001), have a higher eGFR (mean
49.7 ml/min/1.73 m2 vs 40.4 ml/min/1.73 m2, p < 0.001), and have earlier stage renal disease (CKD Stage 1: 15.7% vs
5.1%, x2 < 0.0005) than those without GRD.
Conclusions: The proportion of GRD amongst an Australian adult CKD population in specialty renal practice is
similar to past estimations. GRD is a significant cause for CKD and for RRT commencement, presenting
opportunities for ongoing longitudinal study, directed therapeutics and clinical service redesign.
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Chronic Kidney Disease (CKD) is common, being pre-
sent in approximately 1 in 7 Australians aged 25 years
or older [1]. Whilst etiologically heterogeneous, up to
20% of cases of CKD are thought to be due to genetic
forms of renal disease [2-4]. This approximates to a popu-
lation prevalence with Genetic Renal Disease (GRD) of
32,000/million aged ≥25 years, which, in absolute numbers
represents 422,842 Australians or 3.2% of the Australian
population ≥25 years in 2011 (www.abs.gov.au). This* Correspondence: andrew.mallett@health.qld.gov.au
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unless otherwise stated.population shares the higher morbidity, mortality and
health care requirements [5] common to all patients with
CKD. It is unclear however whether CKD due to various
forms of GRD carries the same risks as that associated
with other CKD aetiologies. This requires longitudinal
studies and further clarification. Admissions for those
progressing to end stage kidney disease (ESKD) requir-
ing renal replacement therapy (RRT), alone are pres-
ently the most common cause for hospital admission in
Australia [6,7]. Of the 2,453 patients who commenced
RRT in Australia during 2011, GRD was the cause for
ESKD in 13% [8].
The prevalence of GRD in the Australian paediatric
population is 70.6/million aged <20 years [9], though thisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Mallett et al. Orphanet Journal of Rare Diseases 2014, 9:98 Page 2 of 9
http://www.ojrd.com/content/9/1/98may be an underestimate. The GRD spectrum is vast,
encompassing many different diseases and disease grou-
pings. Causative genetic and pathobiological understan-
ding of some is advanced, as in ADPKD [10-13] and
Alport Syndrome [14-18]. For many other forms of
GRD such as ciliopathies [19,20] and congenital anom-
alies of the kidney and urinary tract (CAKUT) [21-26]
this is much less so but continues to expand every year.
Emerging research tools such as next generation genetic
sequencing and induced pluripotent stem cell technol-
ogy are enabling significant acceleration of discovery
and understanding. Improved disease understanding be-
gets the emergence and rigorous study of potential treat-
ments, as we are realising for ADPKD [27-30], Alport
Syndrome (AS) [31-38], and Tuberous Sclerosis Complex
(TSC) [39-42]. Even for more rare forms of GRD such
as atypical haemolytic uremic syndrome (aHUS) [39-42]
and Fabry’s disease (FD) [43-47], new therapeutic mo-
dalities are emerging to challenge historical paradigms
of unavoidable decline in renal function, excess bur-
dens of morbidity and mortality, and decreased quality
of life.
The spectrum of GRD seen in the adult versus pae-
diatric populations is likely to be different. Autosomal
Dominant Polycystic Kidney Disease (ADPKD) is the
most striking example, with clinical disease onset and
diagnosis largely in adulthood [48] and relatively high
disease prevalence at 1/400-1000 population [49-55].
Compared to paediatric populations, ADPKD imparts
a significant impact upon GRD prevalence estimates
amongst adults.
In order to more precisely profile GRD in an adult
CKD population, we have utilised a large and current
Australian population based dataset. The CKD.QLD re-
gistry is a research platform of the Chronic Kidney Dis-
ease in Queensland collaboration (CKD.QLD), formed in
2009 in the third most populous Australian state/ter-
ritory. It is a collaborative, multidisciplinary research
and practice improvement network, which encompasses
all public hospital adult nephrology practices across
Queensland, which are estimated to provide services to
10,800 CKD patients. This report describes the pre-
valence of GRD in the first 2,935 consented patients
at five sites. These five sites currently provide primary
public nephrology services for an estimated 58% of the
Queensland resident population, and represent inner
metropolitan, outer metropolitan, regional and rural set-
tings. This size and diversity of service locations increases
data sensitivity, power and translatability. Understanding
of the epidemiology of CKD more broadly and GRD more
specifically is hypothesised to be a pre-requisite for effec-
tive health service provision, planning and realignment,
and for identification of locally unaddressed research
priorities.Methods
The CKD.QLD registry of all consented patients at five
sites as at December 2013 was examined. All patients
had clinically diagnosed CKD, were 18 years or older and
had attended public nephrology practices in Queensland.
Information on gender, age, renal function, CKD stage,
and CKD aetiology was available. CKD aetiology was re-
corded and coded according to the coding protocols of
the Australia and New Zealand Dialysis and Transplant
registry (ANZDATA). Up to four primary renal diagnoses
were listed for each patient and reflected the clinical diag-
noses provided by their treating clinicians.
All potentially genetic or inheritable forms of renal di-
sease were extracted from the CKD.QLD registry, and
compared with all other CKD patients in the registry.
Cases were found by key word searches of the entire r-
egistry followed by systematic and exhaustive manual re-
view of all records in the registry. The search included,
but was not limited to, the key words ADPKD, autoso-
mal recessive polycystic kidney disease (ARPKD), nephro-
nophthisis, syndromic ciliopathies, Alport Syndrome (AS),
thin basement membrane nephropathy (TBMN), medul-
lary cystic kidney disease (type 1, 2 and unspecified; in-
cluding autosomal dominant tubulointerstitial kidney
disease, familial juvenile hyperuricemic nephropathy and
UMOD nephropathy), tuberous sclerosis complex (TSC),
Fabry Disease (FD), atypical haemolytic uremic syndrome
(aHUS), nail-patella syndrome, familial focal segmental
glomerulosclerosis (FSGS), Bartter Syndrome, Gitelman
Syndrome, and congenital anomaly of the kidney and
urinary tract (CAKUT). The inclusion of physician-
diagnosed CAKUT (including vesico-ureteric reflux)
is open to discussion as described by Fletcher et al.
[9] in their study of the prevalence of GRD in the
Australian paediatric population. This group of pa-
tients has also been included in this study (despite
the variable phenotypes), in recognition of the clear
description and ongoing discovery of causative genes.
Further, their inclusion aids comparison to the local
paediatric study, for a more representative and simi-
larly aligned overview of GRD across the lifespan.
Data were collected on the number of patients with
each condition, their gender, age (overall and 5 year
age groups), estimated glomerular filtration rate (eGFR,
ml/min/1.73 m2; CKD-EPI equation), and current CKD
stage at consent. These were analysed in comparison
to all other CKD.QLD registry patients as well as
in subgroups using relative risk (p value and 95%
confidence intervals), chi2 (x2) for significance, and
T-test or Mann–Whitney Test where applicable. Lon-
gitudinal data on renal dysfunction progression were
collected and analysed for the subgroup of patients
from one site where this was additionally available
(ΔeGFR). This single site group constituted 956 patients,
Mallett et al. Orphanet Journal of Rare Diseases 2014, 9:98 Page 3 of 9
http://www.ojrd.com/content/9/1/98representing 32.6% of the total CKD.QLD cohort of 2,935
patients.
For comparison with the incident Australian and New
Zealand RRT cohorts, data were extracted from the pub-
lished ANZDATA registry reports 2001 to 2012 inclusive
(www.anzdata.org.au), which describes all incident RRT
patients from 01.01.2000 to 31.12.2011. Using the paedi-
atric (aged <18 yrs) primary renal diagnosis data from
two six year periods (2000–2005 and 2006–2011) and
primary renal diagnosis data for all incident patients
from each individual year 2000 to 2011, an extrapolation
of the adult (aged ≥18 years) GRD and non-GRD co-
horts could be made for each of these six year periods.
These cohorts were then compared with the GRD and
non-GRD CKD.QLD cohorts using relative risk and chi2
(x2) for significance.
Prevalence was calculated as a proportion of the total
CKD.QLD population (percentage) and as a propor-
tion of the population 18 years or older (number per
million population) served by the 5 sites according to
the Queensland Health 2013 Hospital and Health Service
boundaries (www.health.qld.gov.au) as at the 2011 census
(www.abs.gov.au).
Results
CKD and general population prevalence
A total of 287 patients had a GRD Primary Renal Diag-
nosis, representing 9.8% of the total cohort of 2,935Table 1 Specific genetic renal diseases in the adult CKD popu
Genetic renal disease Number CKD cohor
prevalence
Autosomal dominant polycystic kidney disease 127 4.3%
Congenital anomalies of the kidney and urinary tract 106 3.6%
Medullary cystic kidney disease 15 0.5%
Thin basement membrane nephropathy 12 0.4%
Alport syndrome 5 0.2%
Tuberous sclerosis complex 5 0.2%
Atypical hemolytic uremic syndrome 3 0.2%
Birt-Hogg-Dube syndrome 3 0.1%
Membranoproliferative Glomerulonephritis
Type 2 (“Dense deposit disease”)
2 0.1%
Fabry disease 2 0.1%
Nephronophthisis 2 0.1%
Familial focal segmental Glomerulosclerosis 2 0.1%
Gitelman syndrome 1 0.1%
Nail Patella syndrome 1 0.1%
Renal tubular acidosis 1 0.1%
TOTAL 287 9.8%
*Based upon the 2011 Australian bureau of statistics population of 2,086,055 persons aadults with CKD. The most common specific GRD diag-
noses (Table 1) were ADPKD (4.3%), CAKUT (3.6%),
and MCKD (0.5%).
The general population prevalence of CKD derived
from this CKD cohort is 1,407 cases per million popula-
tion 18 years or over. The population prevalence of CKD
due to GRD is 138 cases per million population 18 years
or over (Table 1).
CKD population characteristics
There were GRD cases present at all 5 sites with variable
distribution (Table 2). One site (Site 1) had the largest
number of CKD patients overall, as well as the highest ab-
solute number and proportion of GRD, which was signifi-
cant compared to the other 4 sites (13.7% vs 7.5%; x2 <
0.0005; Relative Risk 1.4, 95% CI 1.2-1.6). Conversely, Site
3 had the second largest number of CKD patients overall
but with a significantly lower proportion of GRD (6.4% vs
11.4%; x2 < 0.0005; Relative Risk 0.6, 95% CI 0.5-0.8).
There were significantly more women with GRD as
compared to the non-GRD CKD population (54.0% vs
45.6%; x2 0.007; Relative Risk 1.4, 95% CI 1.1-1.7). Both
mean and median age of GRD patients was younger than
those with CKD not due to GRD (52.6 yrs vs 69.3 yrs,
t(2933) = 14.7, p < 0.001; 53.4 yrs vs 66.4 yrs, U(2935) =
54519, Z = 12.1, p < 0.001). Those with GRD were repre-
sented in significantly greater proportions in all 5 yr age
groups below 56 yrs that were analysed.lation (n = 2935)
t General population
prevalence (per million







60.88 50.72/46 53.37/53.53 51.18%
50.81 41.74/38 54.52/56.90 48.11%
7.19 45.87/39 48.65/49.27 60%
5.75 82.33/91 51.04/57.01 91.67%
2.40 85.4/91 29.46/25.61 80%
2.40 64.4/69 56.34/51.63 100%
2.40 45.67/44 36.66/41.44 100%
1.44 69.33/91 55.79/52.75 100%
0.96 48/48 61.25/61.25 50%
0.96 88/88 57.77/57.77 50%
0.96 40.5/40.5 25.46/25.46 50%
0.96 65/65 30.50/30.50 50%
0.48 91/91 27.89/27.89 100%
0.48 27/27 30.30/30.30 0%
0.48 20/20 81.28/81.28 0%
137.58 49.72/45 52.6/53.39 54.01%
ged 18 years or over residing in the areas served by the 5 sites included.
Table 2 GRD (N = 287) versus non-GRD (N = 2648) CKD population characteristics
Ckd.Qld Sites
GRD Non-GRD GRD Vs Non-GRD
Site Number Proportion of site Number Proportion of site x2 Relative risk (95% Ci)
1 149 13.68% 940 86.32% <0.0005 1.380 (1.221-1.560)
2 30 7.26% 383 92.74% 0.073 0.723 (0.509-1.027)
3 60 6.37% 882 93.63% <0.0005 0.628 (0.498-0.791)
4 24 11.53% 184 88.46% 0.396 1.203 (0.801-1.809)
5 24 8.48% 259 91.52% 0.464 0.855 (0.573-1.275)
Gender
GRD Non-GRD GRD vs Non-GRD
Number Proportion of GRD Number Proportion of Non-GRD x2 Relative risk (95% CI)
Male 132 0.46 1440 0.54 0.007 0.738 (0.592-0.921)
Female 155 0.54 1208 0.46 0.007 1.354 (1.086-1.688)
CKD Stage
GRD Non-GRD GRD vs Non-GRD
CKD stage Number Proportion of GRD Number Proportion of Non-GRD x2 Relative risk (95% CI)
1 45 15.68% 134 5.06% <0.0005 2.714 (2.052-3.591)
2 51 17.77% 277 10.46% <0.0005 1.718 (1.298-2.273)
3a 48 16.72% 475 17.94% 0.628 0.926 (0.689-1.244)
3b 64 22.30% 887 33.50% <0.0005 0.599 (0.458-0.782)
4 53 18.47% 685 25.87% 0.006 0.674 (0.506-0.898)
5 23 8.01% 182 6.87% 0.542 1.160 (0.776-1.734)
unknown 3 1.05% 8 0.30% 0.085 2.808 (1.063-7.417)
T Test/Mann–Whitney Test
Mean eGFR 49.72 40.35 t (2921) = 7.05, p <0.001
Median eGFR 45 37 U (2923) = 445087, Z = 5.3, p <0.001
Age
GRD Non-GRD GRD vs Non-GRD
Mean age 52.6 69.3 t (2933) = 14.65, p <0.001
Median age 53.39 66.42 U (2935) = 545319, Z = 12.12, p <0.001
Age group Number Proportion of GRD Number Proportion of Non-GRD x2 Relative risk (95% CI)
15-20 10 3.48% 8 0.30% <0.0005 5.850 (3.813-8.977)
21-25 20 6.97% 20 0.76% <0.0005 5.421 (3.896-7.543)
25-30 19 6.62% 40 1.51% <0.0005 3.456 (2.346-5.091)
31-35 17 5.92% 59 2.23% 0.001 2.369 (1.535-3.656)
36-40 16 5.57% 81 3.06% 0.027 1.727 (1.088-2.741)
41-45 25 8.71% 89 3.36% <0.0005 2.110 (1.465-3.039)
46-50 24 8.36% 118 4.46% 0.005 1.795 (1.224-2.631)
51-55 33 11.50% 140 5.29% <0.0005 2.074 (1.493-2.881)
56-60 14 4.88% 233 8.80% 0.024 0.558 (0.331-0.940)
61-65 25 8.71% 296 11.18% 0.232 0.777 (0.524-1.152)
66-70 31 10.80% 373 14.09% 0.126 0.759 (0.531-1.085)
71-75 21 7.32% 441 16.65% <0.0005 0.423 (0.274-0.652)
76-80 16 5.57% 350 13.22% <0.0005 0.414 (0.253-0.678)
81-85 12 4.18% 282 10.65% 0.001 0.392 (0.223-0.690)
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Table 2 GRD (N = 287) versus non-GRD (N = 2648) CKD population characteristics (Continued)
86-90 2 0.70% 107 4.04% 0.005 0.182 (0.046-0.721)
91-95 2 0.70% 10 0.38% 0.621 1.709 (0.480-6.087)
96-100 0 0% 1 0.04% 1 0.000 (0.000-0.000)
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than without GRD (49.7 ml/min/1.73 m2 vs 40.4 ml/min/
1.73 m2, t(2921) = 7.1, p < 0.001; 45 ml/min/1.73 m2 vs
37 ml/min/1.73 m2, U(2923) = 445087, Z = 5.3, p < 0.001).
Those with GRD were more likely to have CKD stage 1 or
2 (15.7% vs 5.1%, x2 < 0.0005, Relative Risk 2.7, 95% CI
2.1-3.6; 17.8% vs 10.5%, x2 < 0.0005, Relative Risk 1.7, 95%
CI 1.3-2.3) and those without GRD were more likely to
have CKD stage 3b or 4 (22.3% vs 33.5%, x2 < 0.0005, Rela-
tive Risk 0.6, 95% CI 0.5-8; 8.0%% vs 25.9%, x2 0.006, Rela-
tive Risk 0.7, 95% CI 0.5-0.9).
There was no clear difference in either mean or me-
dian ΔeGFR within or between GRD and non-GRD popu-
lations for the subset of patients from Site 1 (Figures 1; 2)
for whom data on data on renal dysfunction progression
were available.
Major non-GRD causes for CKD included renovascu-
lar disease including hypertension (24.26%, n = 712), dia-
betic nephropathy (22.66%, n = 665), uncertain diagnosis
(15.06%, n = 442), glomerulonephritis not otherwise spe-
cified (3.30%, n = 97), membrano-proliferative glomeru-
lonephritis (2.18%, n = 64), loss of single kidney (2.20%,
n = 64), analgesic nephropathy (1.90%, n = 56), focal seg-
mental glomerulonephritis (1.53%, n = 45), bilateral renalMean change: 49.18 vs 49.23ml/min/m2 over 465days, eGFR +0.04ml/min/m
Median change: 45 vs 44ml/min/m2 over 571days, eGFR -0.64ml/min/m2/yr
Figure 1 Change in eGFR over time in Site 1. GRD patients (n = 120).artery stenosis (0.99%, n = 29), lupus nephritis (0.95%,
n = 28), membranous nephropathy (0.78%, n = 23), lith-
ium nephropathy (0.65%, n = 19), interstitial nephritis
(0.51%, n = 15), anti-neutrophil cytoplasmic antibody as-
sociated nephropathy (0.37%, n = 11), IgA nephropathy
(0.34%, n = 10), and Goodpasture Syndrome (0.2%, n = 6).
Comparison between CKD and RRT populations
GRD was the Primary Renal Diagnosis in 11.3% and 17.5%
of incident Australian and New Zealand Adults commen-
cing RRT between 2006–2011 and 2000–2005 respectively
(Table 3). The prevalence of GRD in the CKD.QLD preva-
lent Australian adult CKD population was significantly
lower compared to both cohorts of incident RRT patients
(2006–2011: 9.8% vs 11.3%, x2 0.014, Relative Risk 0.9,
95% CI 0.8-1.0; 2000–2005: 9.8% vs 17.5%, x2 < 0.0005,
Relative Risk 0.6, 95% CI 0.5-0.7). In both time periods
there was a significantly higher proportion of paediatric
compared to adult cases of GRD incident RRT.
Discussion
Here we describe the prevalence of adults with chronic
kidney disease due to genetic or inheritable aetiologies
within a significant multi-site Australian CKD registry.2/yr
Mean change: 39.7 vs 39.42ml/min/m2 over 456days, eGFR -0.22ml/min/m2/yr
Median change: 36 vs 35.5ml/min/m2 over 536days, eGFR -0.34ml/min/m2/yr
Figure 2 Change in eGFR over time in Site 1. Non-GRD patients (n = 834).
Table 3 GRD in published ANZDATA incident RRT
01.01.2000 to 31.12.2005 01.01.2006 to 31.12.2011








PKD 873 7 866 1106 13 1093
MCGN-II 27 0 27 28 0 28
Familial GN (Alport & Secondary FSGS) 106 12 94 130 4 126
Cystinosis 9 7 2 3 2 1
Oxalosis & Fabry Disease 12 0 12 9 0 9
MCKD 80 17 63 73 8 65
HUS 52 6 46 59 12 47
CAKUT 637 111 526 674 107 567
TSC 3 0 3 1 0 1
Alagille Syndrome 0 0 0 1 0 1
NPS 1 0 1 1 0 1
SRNS 12 0 12 7 0 7
BHD & VHL 5 0 5 1 0 1
Fanconi RTA 11 0 11 8 0 8
TOTAL GRD 1828 160 1668 2101 146 1955
TOTAL Non-GRD 9860 357 9503 17584 308 17276
% of Cohort GRD 18.52% 44.82% 17.53% 11.94% 47.40% 11.31%
Adult GRD CKD vs GRD Incident RRT 9.8% vs 17.53%, x2 < 0.0005, Relative risk 0.582,
95% CI 0.520-0.651
9.8% vs 11.31%, x2 0.014, Relative risk 0.869,
95% CI 0.790-956
Paediatric vs Adults GRD Incident RRT 44.81% vs 17.53%, x2 < 0.0005, Relative risk 3.574,
95% CI 2.919-4.375
47.4% vs 17.53%, x2 < 0.0005, Relative risk 6.645,
95% CI 5.338-8.272
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dissimilar to historical estimates [2-4], and provides an
evidence-based measurement where one has not been
previously clearly described. Furthermore, this finding is
clinically similar to, though significantly less than, the
11.3% prevalence of GRD in the most recent cohorts of
patients commencing RRT in Australia and New Zealand.
Together these suggest that in an Australasian context,
approximately 1 in 10 patients with recognised renal dis-
ease coming to the attention of renal specialists would be
expected to have a genetic aetiology.
Some regional differences may exist, as evidenced by
inter-site differences within the CKD cohort studied.
These might be explained by differing clinician diagnostic
propensities, referral bases, primary care referral models,
available clinical services, and clustering of extended af-
fected families by region. The explanation for female pre-
ponderance in the GRD population, compared to the male
majority in the non-GRD population, is unclear. It would
however be expected that many of the female patients
with potentially X-linked diseases such as either AS or
TBMN would be more likely to have CKD rather than
ESKD. This was observed in our study, however these
groups accounted for less than 6% of the GRD cohort. A
near even gender balance was observed in the 81% of
the GRD cohort accounted for by the two largest GRD
sub-groups (ADPKD, CAKUT). This suggests that the
increased female representation in some small GRD
sub-groups may be due to disease specific features of in-
heritance, rather than other factors, and that this gender
bias amongst a minority is responsible for the overall
observation of female predominance.
Unsurprisingly those with GRD were significantly youn-
ger, in keeping with a genetic aetiology and renal pa-
thobiology progressing throughout the lifespan and
commencing early in life. An additional cause may be
younger age of diagnosis and commencement of renal
follow-up due to more proactive screening triggered by
knowledge of affected family members. This could also
explain the better preserved renal function observed in
those with GRD. The absence of clearly more rapid
renal dysfunction progression in the small and short-
term single site cohort of patients suggests that patients
with GRD are presenting to nephrologists earlier than
those without GRD, either as a result of known family
history, symptoms not exhibited best by renal dysfunc-
tion, or even extra-renal phenotypes. This group would
also be less likely to have a pre-existing background of
cardiovascular disease or metabolic dysfunction that
may be associated with renal function decline.
The cause for the observed decrease in adult GRD inci-
dent RRT from 2000–2005 (17.5%) to 2006–2011 (11.3%)
is not clear. During this time period there was mini-
mal change in the paediatric GRD incident RRT cohortprevalence (Table 3). One explanation is a dilutional effect
exerted by non-GRD causes for renal disease amongst
adults due to increasing prevalence and/or more rapid
renal dysfunction progression. A candidate for this is
diabetic nephropathy, the proportion of which increased
within the incident RRT cohort in a sustained and inex-
orable fashion from 24.8% in 2000 to 36.5% in 2011.
Even though absolute numbers of incident RRT due to
GRD in adults increased from 1,668 in 2000–2005 to
1,955 in 2006–2011 this was modest by comparison to
vastly increasing overall numbers of overall adult RRT
patients (9,514 in 2000–2005 to 17,284 in 2006–2011).
No historical data on primary renal diagnosis are avail-
able for this CKD cohort during that 12 year timeframe
of considerable change within the relevant RRT popula-
tion. Ongoing CKD cohort surveillance and future ana-
lyses will be important to enable hypothesis generation
in the future.
Some GRD’s were notably absent in this cohort, in-
cluding Dent Disease, Renal Cysts and Diabetes (RCAD)
Syndrome, Cystinuria, Bartter Syndrome, Familial Hypo-
magnesaemic Hypercalciuria, and Gordon Syndrome.
Whilst the causes for this are not clear, some may be ab-
sent due to misdiagnosis (RCAD vs ADPKD; Bartter
Syndrome vs Gitelman Syndrome) or being predomin-
antly cared for in non-renal specialty clinics (Gordon
Syndrome in Hypertension Clinic; Cystinuria in Urology).
There is also some chance that population prevalence may
be very low. The diagnoses in this registry are clinician de-
rived and it is not clear as to the proportion of reported
GRD cases that have been confirmed with a molecu-
lar genetic diagnosis. Despite this, the major two GRD’s
(ADPKD, CAKUT) are predominantly diagnosed clinic-
ally, even in the absence of a confirmatory molecular
genetic diagnosis.
The population prevalence of GRD within the adult
CKD population that we present as disease prevalence
per million aged ≥18 years is likely to be an underesti-
mation in the general community. There are three main
causes for this. The first is under-ascertainment, as not
all cases of CKD and/or GRD seen in public hospital
nephrology practices are being enrolled in CKD.QLD.
The second is that some cases of CKD and/or GRD are
seen in private nephrology practice and thus not en-
rolled in the CKD.QLD registry. Lastly, there are likely
cases of CKD and GRD resident in the service areas
of these 5 sites that remain miscoded, undiagnosed,
unknown, or unreferred to any nephrology services.
Despite these limitations, the percentage prevalence
is however likely to be representative of the broader
CKD population. As the CKD.QLD registry grows and
matures, and other Australian CKD registries emerge, a
larger study would be warranted to confirm and corre-
late these findings.
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The prevalence of GRD within this CKD population is
similar to, although at the lower range, of prior general
estimations. These patients are younger with higher
levels of renal function and are more likely to be female.
Their renal dysfunction was not observed to deteriorate
faster than other CKD patients. A significant absolute
number and proportion of those starting RRT continue
to have GRD. This information is important for multi-
disciplinary patient counselling and management. The
finding of a significant and identifiable minority of pa-
tients with CKD having GRD confirms this group as
a priority target for optimised future service planning
within the emerging paradigm of personalised medi-
cine and healthcare. This also allows the early identi-
fication and management of at risk family members,
prior to them developing significant renal dysfunction.
Future surveillance of this and other CKD cohorts is
required to correlate and corroborate these findings
as well as to observe future changes.
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